530 / 1851
Targeted treatments
•
Anti-angiogenesis
–
Bevacizumab
•
Tyrosine kinase inhibitors
–
Sunitinib, sorafenib, imatinib,
pazopanib, cediranib
•
EGFR inhibitors
–
Gefitinib, erlotinib, cetuximab,
lapatinib, trastuzumab,
panitumumab
•
Ribonucleotide reductase
inhibitor
–
Triapine
•
Immunotherapy
–
Adoptive T-cell therapy
–
ADXS11-001 (axamilogene)